Abarceo Pharma
  • About
  • Team
    • Management
    • Board Members
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page

Investing in Life Science 2024 – Presentation

by SD-AbarceoPharma | Nov 14, 2024 | Events, Investors, News & Press releases

Adam Bruce, CEO & Chair of Abarceo Pharma, presents at Investing in Life Science – From Seed To Success. About the event On September 12, 2024, BioStock and Vator Securities hosted the investment-focused event, Investing in Life Science: From Seed to...

Recent Posts

  • Can we reverse diabetes? – Abarceo Pharma aims to develop the solution of the future
  • Investing in Life Science 2024 – Presentation
  • Investing in Life Science 2024 – Interview
  • World Diabetes Day
  • Bio-Europe® 30 years

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2022 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy